ArticleBMC infectious diseases2015
How much European prescribing physicians know about invasive fungal infections management?
Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Optimizing antifungal therapy: a systematic review of pharmacist interventions, stewardship approaches, and outcomes.Frontiers in medicine · 2024Pooled it
- Trial
- Non-Interventional, Retrospective, Multicenter Study on the Renal Safety of Liposomal Amphotericin B in Critically Ill Patients with Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2026Article
- Knowledge, Attitudes and Practices of Physicians Regarding Antifungal Therapy in Tertiary Care Patients: A Cross-Sectional Survey in Greece.Pathogens (Basel, Switzerland) · 2026Article
- Intervention studies and antimicrobial resistance in Italy: An overview of the latest evidence.Journal of global antimicrobial resistance · 2026Review
- The Patterns and Appropriateness of Systemic Antifungal Prescriptions in a Regional Hospital in Hong Kong.Antibiotics (Basel, Switzerland) · 2025Article
- Baseline knowledge on chronic pulmonary aspergillosis and tuberculosis among health care workers involved in tuberculosis care in Uganda.IJID regions · 2025Article
- The Effects of COVID-19 on Antifungal Prescribing in the UK-Lessons to Learn.Journal of fungi (Basel, Switzerland) · 2024Article
- Ecotoxicity and Mutagenicity Assessment of Novel Antifungal Agents VT-1161 and T-2307.Molecules (Basel, Switzerland) · 2024Article
- Review
- Laboratory and clinical management capacity for invasive fungal infections: the Italian landscape.Infection · 2024Article
- Evaluation of Systemic Antifungal Prescribing Knowledge and Practice in the Critical Care Setting among ICU Physicians and Clinical Pharmacists: A Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2023Article
- Invasive fungal infections in hematologic malignancies: Incidence, management, and antifungal therapy.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Review
- Antifungal stewardship in solid organ transplantation.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- The Effect of the Pandemic on Antifungal Use: What Has Changed?Infectious diseases & clinical microbiology · 2022Article
- The Role of Diagnostics-Driven Antifungal Stewardship in the Management of Invasive Fungal Infections: A Systematic Literature Review.Open forum infectious diseases · 2022Review
- Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.GMS hygiene and infection control · 2022Article
- The Current State of Antifungal Stewardship in Immunocompromised Populations.Journal of fungi (Basel, Switzerland) · 2021Article
- Article
- Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.The Journal of infectious diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of systemic antifungal agents has increased in most tertiary care centers. However, antifungal stewardship has deserved very little attention. Our objective was to assess the knowledge of European prescribing physicians as a first step of an international program of antifungal stewardship.
methodsStaff physicians and residents of 4 European countries were invited to complete a 20-point questionnaire that was based on current guidelines of invasive candidiasis and invasive aspergillosis.
results121 physicians (44.6% staff, 55.4% residents) from Spain 53.7%, Italy 17.4%, Denmark 16.5% and Germany 12.4% completed the survey. Hospital departments involved were: medical 51.2%, ICUs 43%, surgical 3.3% and pharmaceutical 2.5%. The mean score of adequate responses (± SD) was 5.8 ± 1.7 points, with statistically significant differences between study site and type of physicians. Regarding candidiasis, 69% of the physicians clearly distinguished colonization from infection and the local rate of fluconazole resistance was known by 24%. The accepted indications of antifungal prophylaxis were known by 38%. Regarding aspergillosis, 52% of responders could differentiate colonization from infection and 42% knew the diagnostic value of galactomannan. Radiological features of invasive aspergillosis were well recognized by 58% of physicians and 57% of them were aware of the antifungal considered as first line treatment. However, only 37% knew the recommended length of therapy.
conclusionsThis simple, easily completed questionnaire enabled us to identify some weakness in the knowledge of invasive fungal infection management among European physicians. This survey could serve as a guide to design a future tailored European training program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.